Algernon Pharmaceuticals Inc. C.AGN

News from AGN's Ifenprodil proof of concept study

[StockHawk1]

Algernon Pharmaceuticals Inc. (AGN.c $AGNPF) recently announced that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating its drug, Ifenprodil, for the potential treatment of idiopathic pulmonary fibrosis & chronic cough.

65% in the study of patients had statistically significant stable or improved forced vital capacity (aka the amount of air that can be forcibly exhaled) capacity over the 12-week treatment period.

Additionally, 30% of subjects achieved a 50% reduction in the average number of coughs per hour over 24 hours from baseline to week 12.

Personally, I think these results are pretty promising and definitely worth looking into if you are interested in the biotech sector: https://lifesciencesbc.ca/members/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough/